Title
The autocrine role of tumor necrosis factor in the proliferation and functional differentiation of human lymphokine-activated T killer cells (T-LAK) in vitro.

Permalink
https://escholarship.org/uc/item/12060932

Journal
Cytokine, 4(5)

ISSN
1043-4666

Authors
Innins, EK
Gatanaga, M
Van Eden, M
et al.

Publication Date
1992-09-01

DOI
10.1016/1043-4666(92)90083-4

License
https://creativecommons.org/licenses/by/4.0/ 4.0

Peer reviewed
THE AUTOCRINE ROLE OF TUMOR NECROSIS FACTOR IN THE PROLIFERATION AND FUNCTIONAL DIFFERENTIATION OF HUMAN LYMPHOKINE-ACTIVATED T KILLER CELLS (T-LAK) IN VITRO

Elizabeth K. Innins, Maki Gatanaga, Marc Van Eden, Katherine L. Knudsen, Gale A. Granger, Tetsuya Gatanaga

The autocrine role of tumor necrosis factor α (TNF) in the proliferation and functional differentiation of human lymphokine-activated T-killer cells (T-LAK) in vitro was investigated. Human peripheral blood lymphocytes initially stimulated with IL-2 and phytohemagglutinin-P (PHA) for 48 h will proliferate for long periods in vitro in the presence of IL-2. These T-LAK cells have been shown to be 95% CD3 positive. Employing ELISA techniques, greater than 500 pg/ml of TNF was found to be released in the supernatants of these cells during the first 5 days of culture. However, the levels dropped to 100–200 pg/ml by days 7–10. T-LAK cells grown from days 7 to 10 in the presence of IL-2 and rabbit anti-TNF were significantly growth inhibited (up to 23%). The cytolytic activity of T-LAK cells grown from days 0 to 7 in the presence of anti-TNF was also decreased (up to 75%). Phenotypic analysis of these anti-TNF treated T-LAK cells revealed a decrease in CD8 expression (up to 12%) and increase in CD4 expression (up to 27%) when compared with control cells. The data suggest that TNF has a regulatory role in the growth and functional differentiation of these human T-LAK cells.

Lymphocytes collected from peripheral blood or tumor sites can be co-cultured with IL-2 to become lymphokine-activated killer cells (LAK), or tumor-infiltrating lymphocytes (TIL), respectively. These cells have the ability to lyse a wide range of tumor targets, and are currently being used in a variety of clinical trials. Because LAK and TIL cells have been found to secrete cytokines, study has focused on the role(s) that cytokines may play in the proliferation, differentiation and cytotoxic activity of these cells.

There are two general classes of LAK cells: those which originate predominantly from NK precursors and those which have T-cell precursors. Lymphocytes from peripheral blood which are initially stimulated with phytohemagglutinin-P (PHA) and IL-2 become long term, non-genetically restricted lymphokine-activated T killer cells (T-LAK). Dett et al. showed that upregulation of the expression of tumor necrosis factor α (TNF) and its receptors occurred when the cells were co-cultured with IL-2 plus:IL-1β, IL-4 or IL-6.

TNF is a pleiotropic cytokine produced predominantly by activated macrophages and to a much lesser degree by lymphocytes. TNF is known to first bind to specific cell surface receptors, two of which differ.
B cells, T cells, and NK cells in vitro.\textsuperscript{13–19}

This study examines the autocrine role of human TNF in the proliferation and differentiation of IL-2 stimulated human T-LAK cells in vitro. We found reducing the levels of endogenous TNF with polyclonal antiserum to TNF affects the proliferation, differentiation and cytolytic activity of T-LAK cells. These data suggest that TNF may have important roles in both the growth and functional differentiation of IL-2 stimulated human T-LAK cells.

RESULTS

**TNF Levels and Phenotypic Expression of Developing Human T-LAK Cultures**

In-vitro PBMC were stimulated with PHA and co-cultured with IL-1 as described in the Materials and Methods. As shown previously,\textsuperscript{7} cell division began in 4–5 days and cells doubled every 20–24 h during the period of these studies. Phenotypic expression of CD3, CD4 and CD8 was measured by FACS analysis on days 2, 5 and 7. The results of a representative experiment are shown in Table 1. CD3 and CD8 expression increased (from 84% to 96%, and from 34% to 51%, respectively) during this culture period, while CD4 expression decreased from 55% to 40%. This pattern was seen in all cultures tested, although the absolute % of antigen expression differed from donor to donor. Supernatants from these cultures were assayed by ELISA for TNF on days 2, 5, 7 and 9. The results of a representative experiment are shown in Fig. 1. TNF was present in high concentrations (> 500 pg/ml) for the first 5 days of culture; however, levels dropped thereafter. This pattern was seen in each of at least 3 T-LAK cultures tested, although absolute cytokine concentrations varied from donor to donor.

**The Effect of Reduced TNF Levels on T-LAK Cell Proliferation**

Polyclonal rabbit anti-TNF or NRS was added to 7-day growing T-LAK cultures at final concentrations of 1:200, 1:2000 and 1:20 000. After 4 days at 37°C, the resulting viable cell numbers were calculated and compared with NRS-treated control cultures. Figure 2 shows the results of a representative experiment and is expressed as % growth inhibition. Anti-TNF dilutions of 1:200, 1:2000 and 1:20 000 inhibited T-LAK growth 25%, 9% and 3%, respectively, when compared to NRS cultures. Dye exclusion tests showed no significant viability differences between cultures incubated with anti-TNF and those incubated with NRS (data not shown).

![Figure 1. TNF production by IL-2 stimulated human T-LAK cells in vitro.](image1)

**The Effect of Reduced TNF Levels on T-LAK Cytolytic Activity**

T-LAK cells grown continuously from the start of culture (days 0–7) in the presence of 1:200 anti-TNF or NRS were tested for their capacity to induce cytolysis of K562 cells in vitro on day 7 of cul-

![Figure 2. The effect of polyclonal anti-TNF on the proliferation of T-LAK cells.](image2)

### TABLE 1. Phenotype expression developing T-LAK cells in vitro.

| Antigen | Day 2 | Day 5 | Day 7 |
|---------|-------|-------|-------|
| CD3     | 84    | 95    | 96    |
| CD4     | 55    | 47    | 40    |
| CD8     | 34    | 44    | 51    |

T-LAK cells were analyzed by FACScan flow cytometry for expression of surface antigens on days 2, 5 and 7 of culture. Results are expressed as % positive cells.
The data presented in Fig. 3 are representative of the results obtained from three separate experiments, conducted with T-LAK cells from three different donors. The cytolytic activity of T-LAK cells which were treated with anti-TNF were inhibited from 17-45% at effector/target (E/T) ratio of 25:1 and 45-75% at E/T ratio of 10:1. The percentage of inhibition of cytolysis is even higher at lower E/T ratios (data not shown). In additional studies, we found almost the same degree of suppression of cytolytic activity when these cells were tested on another target cell line, RAJI.

The Effect of Reduced TNF Levels on the Development of Cell Phenotype

The phenotype of T-LAK cells grown continuously from the start of culture (days 0-7) with anti-TNF, or NRS (final dilution 1:200) were analysed on day 7. Figure 4 shows the data from 3 representative experiments from three different donors. Cultures maintained in anti-TNF serum showed a 5-27% increase in CD4 expression when compared with cells cultured in NRS. In contrast, CD8 expression was decreased by 8-12% when compared with NRS supplemented cultures.

DISCUSSION

The role of endogenously produced cytokines in the autocrine control of the proliferation, differentiation and effector function of IL-2 stimulated lymphocytes is an important issue to analyse. It has been previously reported that IL-2-stimulated human PBMC cultures release various cytokines, including TNF, LT, IL-1α, and IFN-γ. It is becoming apparent that TNF has a role in the maturation and expression of cytolytic activity of IL-2 stimulated human NK-derived LAK cells, and T-cell-derived tumor infiltrating lymphocytes (TIL) cells in vitro. Exogenous TNF has been found to synergize with low levels of IL-2 in the generation of LAK cell cytolytic activity in vitro. This effect is thought to occur through the TNF-mediated upregulation of high affinity IL-2 membrane receptors, making these cells more responsive to IL-2. The increase in LAK cytolysis was not accompanied with changes in cell proliferation in these cultures, however. Recently, it has been reported that TNF receptors are involved in the autocrine control of both cytotoxicity and proliferation of IL-2 stimulated NK derived LAK cultures.

Our studies are the first to examine the effects of endogenous TNF on the proliferation and differentiation of human (T-cell derived) T-LAK cells. In these cultures, we first upregulate IL-2 receptor expression on PBMCs with PHA and simultaneously co-culture with IL-2 for 48 h, then subsequent cultures are conducted in IL-2 alone. This results in a population of CD3 positive/CD16 negative T-LAK cells which will proliferate in the presence of IL-2 for long periods (up to 6-8 months) in vitro. We also detected that high levels of exogenous human recombinant TNF inhibit and low levels enhance the IL-2 driven cell proliferation in these cultures (data not shown). This result was further supported by the finding here presented that antisera which neutralize TNF bioactivity also inhibit the growth of T-LAK cells in these cultures. Preliminary data indicate that these anti-TNF treated cultures express increased 75 kDa TNF receptors and decreased IL-2 receptor levels compared with T-LAK cultures grown in NRS (data not shown). It should be noted that these cells produce...
high levels of endogenous TNF which peak during the first 3–5 days of culture, and drop sharply thereafter. Accordingly, the inhibitory effects of anti-TNF sera were only noted 5 days after these cultures were induced, and after endogenous levels of TNF had declined to lower levels (data not shown). These results imply TNF had little or no growth regulatory effect during the first few days of culture, or that levels of TNF were so high that the antibodies were unable to completely neutralize TNF's proliferation effect.

We also found that endogenously produced TNF affects the expression of cytotoxic effector function of these T-LAK cells in vitro. Our data clearly indicate that lowering levels of endogenously produced TNF with polyclonal antibodies caused the downregulation of CD8 and CD4 glycoproteins on the T-LAK cell surface. Cultures continuously supplemented with anti-TNF had decreased CD8 and increased CD4 expression by day 7 when compared with NRS treated control cells. Interestingly, preliminary work has shown that T-LAK cells grown in anti-LT (TNF-beta) have slightly lower cytotoxicity but the opposite effect on phenotype (increased CD8 and decreased CD4). Further studies are underway in our laboratory to investigate this apparently contrasting effect of these two largely homologous cytokines. The different levels of killing activity of these T-LAK cells may be due to selection of certain subsets present in the original PBMC culture. We find the addition of exogenous TNF had no effect on T-LAK phenotype when added after day 7 of culture (data not shown). These results suggest that TNF may also effect the differentiation and maturation of different populations of T-cells present in these cultures.

Collectively, these results suggest that while TNF is not a major lymphocyte product, it is important in the autocrine control of T-LAK cell growth, differentiation, maturation and expression of effector functional activity in vitro. Thus, IL-2 alone is not sufficient to induce functional activity but acts as a growth factor. It appears that endogenously produced TNF is needed for both the proliferation and differentiation of these cells in vitro. While the precise mechanisms operating in vivo are still unknown, these findings may be important in the understanding and eventual improvement of immunotherapies employing T-cell derived effector cells.

**MATERIALS AND METHODS**

**Cytokines and Polyclonal Antibodies**

Recombinant human tumor necrosis factor-α (TNF) (specific activity $1.0 \times 10^7$ U/mg) was supplied by Genentech Corp. (South San Francisco, CA). Recombinant human IL-2 (specific activity $3.3 \times 10^6$ U/mg) was obtained from the Cetus Corp. (Emeryville, CA). Polyclonal antisera specifically reactive to human recombinant TNF was generated in New Zealand white rabbits after repeated injections according to the method of Vaitukaitis. Each ml of these antisera was able to specifically neutralize $5 \times 10^9$ U of TNF cytolytic activity against the L-929 murine fibroblast line.

**Collection of Human Peripheral Blood Mononuclear Cells (PBMC)**

Human PBMC were collected from peripheral venous blood of normal donors which was defibrinated, diluted with an equal volume of phosphate-buffered saline (0.01 M phosphate 7.2 pH, 0.15 M NaCl) (PBS) and separated by density gradient centrifugation on 1.077 Histopaque (Sigma Chemical Co., St. Louis, MO) as described previously. The PBMC were collected from the interface and further washed to remove the remaining Histopaque by alternate centrifugation (500 $\times$ g for 10 min) and resuspension in PBS. After the final wash, PBMCs were resuspended in AIM-V (GIBCO, Grand Island, NY) with 2% heat-inactivated fetal calf serum (FCS) (GIBCO) and the cells were counted using a Spotlite hemacytometer. These cells were 99 to 100% viable, as determined by the trypan blue exclusion test.

**Generation of Human Lymphokine-activated T Killer Cells (T-LAK)**

Human PBMC were initially cultured in AIM-V with 2% FCS supplemented with 400 U/ml of IL-2 and 0.4 µg/ml phytohemagglutinin-P (PHA) (Sigma). The PBMC were cultured at a density of $2.0 \times 10^6$ cells/ml in 25 cm² tissue culture flasks in a manner similar to the method described by Ingram et al. After 48 to 72 h at 37°C, viable cells were counted and resuspended at 0.5 $\times 10^6$ cells/ml in AIM-V with 2% FCS and 400 U/ml IL-2 (no PHA). These T-LAK cell cultures were then passed in these conditions every 48–72 h.

**ELISA Assay for Human TNF**

 Supernatants were collected from three separate T-LAK cultures after 3, 5, 7 and 9 days in culture. ELISA assays for TNF (Endogen, Boston, MA) were performed according to manufacturer's instructions, and TNF levels were determined by comparison with TNF standards provided in these kits. For determination of the effect of rabbit anti-TNF antibodies on the proliferation and differentiation of T-LAK cells in vitro, cell cultures were supplemented with dilutions of rabbit antisera (NRS or anti-TNF) of 1:200, 1:2000, 1:20 000 for a 3-day interval (days 7–10) after the culture was established. At the end of this period, viable cell numbers were determined as described in Materials and Methods. Data were analyzed for % growth.
inhibition according to the following formula:
\[
\% \text{ growth inhibition} = \left( \frac{\text{control cell number} - \text{test cell number}}{\text{control cell number}} \right) \times 100
\]

For determination of differentiation effects, cell cultures were supplemented with 1:200 NRS or anti-TNF every 48 h from days 0 to 7. At the end of this period, cells were analyzed for their phenotypic expression and cytolitic effectiveness as described below.

**Cytolytic ^51^Cr Release Assay**

Cytolytic assays employing the non-adherent target cell K562 (American Type Culture Collection, Rockville, MD) were performed in 96-well round-bottomed microcytotoxicity plates as described previously. Briefly, radiolabeling of the K562 target cells was accomplished by the addition of 100 μl of ^51^Cr (NEN, Boston, MA) (specific activity 590 mCi/mg, 10 mCi/ml) to 10^6 cells in 1 ml of RPMI + 10% FCS for 18 h at 37°C. The cells were then washed three times by alternate centrifugations (300 x g for 5 min) and resuspensions in RPMI + 10% FCS. A constant number of labeled target cells (2 x 10^4 in 20 μl) was added to microriter wells with various numbers of effector cells in 100 μl 10% RPMI to achieve different effector cell:target cell ratios (25:1, 10:1). Targets and effector cells were incubated at 37°C for 4 h in an atmosphere of 5% CO₂. Cell-free supernatants were removed with Titerteks Supernatant Collection System (Skatron, Lier, Norway) and the amount of ^51^Cr quantitated in an automated Clini-gamma counter (Pharmacia LKB Biotech Inc., Piscataway, NJ). The total ^51^Cr releasable (90-95% of total counts) was determined by lysing the cells with 100 μl of 3% SDS. Spontaneous ^51^Cr release was 1-2% per h. Percent specific cell lysis was determined by the following formula:

\[
\% \text{ specific lysis} = \left( \frac{\text{experimental release} - \text{spontaneous release}}{\text{total release} - \text{spontaneous release}} \right) \times 100
\]

Anti-TNF treated cultures were compared for their cytolitic effectiveness to NRS treated cultures; results are expressed as % inhibition of cytotoxicity as determined by the following formula:

\[
\% \text{ inhibition} = \left( \frac{\text{NRS control specific lysis} - \text{anti-TNF specific lysis}}{\text{NRS control specific lysis}} \right) \times 100
\]

**Flow Cytometric Analysis**

Cell suspensions were analyzed by FACScan (Becton Dickinson, Mountain View, CA). The FACScan was calibrated with the Autocomp program and optimized for each sample tested. Forward scatter thresholds were set in order to eliminate debris and dead cells. Lymphocytes were analyzed by staining the cells for surface antigens with the following fluorescent-labeled monoclonal antibodies obtained from Becton Dickinson: (a) CD3 (Pan T), (b) CD4 (helper-inducer), and (c) CD8 (cytotoxic-suppressor). Cells were incubated with monoclonal antibodies for 30 min on ice and washed twice with PBS with 0.2% sodium azide by alternate centrifugation (500 x g for 5 min) and resuspension. Cells were fixed in 1.0% paraformaldehyde in PBS and stored at 4°C, in the dark, until further analysis. For comparison of NRS and anti-TNF treated cultures data are expressed as % phenotypic change according to the following formula:

\[
\% \text{ phenotypic change} = \left( \frac{\% \text{ anti-TNF cells positive} - \% \text{ NRS cells positive}}{\% \text{ NRS cells positive}} \right)
\]

**REFERENCES**

1. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokinone-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823.

2. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1316.

3. Limb GA, Meager A, Woolley J, Wadhwa M, Biggerstaff J, Brown KA and Wolstencroft RA (1989) Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2. J Immunol 68(4):514.

4. Belldegrun A, Kasid A, Uppenkamp M, Topollian SL, Rosenberg SA (1989) Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142(12):4520.

5. Kruse CA, Mitchell DH, Lillehei, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau W (1989) Interleukin 2-activated lymphocytes from brain tumor patients. Cancer 64:61.

6. Ingram M, Jacques S, Freshwater DB, Techy GB, Hunter SC, Hlaper JT (1987) Salvage immunotherapy of malignant glioma. Arch Surg 122:1483.

7. Dett CA, Gatanaga M, Ininns EK, Cappucini F, Yamamoto RS, Granger GA, Gatanaga T (1991) Enhancement of lymphokine activated T killer cell TNF receptor mRNA transcription, TNF-R membrane expression and TNF/LT release by IL-1β, IL-4 and IL-6 in vitro. J Immunol 146a:1522.

8. Kelker HJ, Oppenheim JD, Stone-Wolf D, Henriksen-DeStefano D, Aggarwal BB, Stevenson II, Vilck J (1995) Characterization of human tumor necrosis factor produced from peripheral blood monocytes and its separation from lymphotxin. Int J Cancer 60:69.

9. Cuturi MC, Murphy M, Costa-Gioni MP, Weinmann R, Perussa B, Trinchieri G (1987) Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med 163:1581.

10. Senneca D, Nedwin GE, Hayflick JS, Sceburug PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV (1984) Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312:724.

11. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T, Granger GA, Lenz R, Raab H, Kohr W, Goeddel DV (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61:361.

12. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RD (1990) A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019:22.

13. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Sheppard HM (1985) Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 230:943.

14. Palombella VJ, Henriksen-DeStefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M (1986) Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163:632.

15. Pfizenmaier K, Scheurich P, Schluter C, Krokne M (1987) Tumor necrosis factor enhances HLA-ABC and HLA-DR gene expression in human tumor cells. J Immunol 138:975.
16. Scheurich P, Thoma B, Ucer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor alpha: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J Immunol 138:1786.

17. Ostensen ME, Thiele DL, Lipsky PE (1987) Tumor necrosis factor enhances cytolytic activity of human natural killer cells. J Immunol 138:4135.

18. Phillip R, Epstein LB (1986) Tumor necrosis factor as an immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma interferon, and interleukin 1. Nature 323:86.

19. Shalaby MR, Aggarwal BB, Rinderknecht L, Svedersky LP, Finkle BS, Palladino MA (1985) Activation of human polymorphonuclear neutrophil function by interferon-gamma and tumor necrosis factors. J Immunol.

20. Owen-Schaub LB, Gutterman JU, Grimm EA (1988) Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor-α and interleukin 2 in the generation of human lymphokine-activated killer cytotoxicity. Cancer Res 48(4):788.

21. Naume B, Shalaby R, Lesslauer W, Espevik T (1991) Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunol 146:3046.

22. Yamamoto RS, Coss J, Vayvegula B, Gupta S, Beamer Y, Jacques S, Jeffes EWB, Carson WE, Jakowitz J, Granger GA (1991) Generation of stimulated, lymphokine-activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma. J Immunol Meth 137:225.

23. Vaitukaitis J, Robbins JB, Nieshlag E, Ross GT (1971) A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol 33:988.

24. Boyum A (1976) Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 5:9–13.

25. Yamamoto RS, Ware CF, Granger GA (1986) The human LT system: XI Identification of LT and TNF-like LT forms from simulated natural killers, specific and non-specific cytotoxic human T-cells in vitro. J Immunol 137:1878–1883.